The results showed that sorafenib significantly inhibited the growth of HepG2 and Huh7 cells, whereas secretory GP73 or PKM2 attenuated the inhibitory effect of sorafenib on the proliferation of HCC cells, and the combination of PKM2 and GP73 significantly reduced the inhibition of sorafenib. Here, PKM is linked to hepatocellular carcinoma.